Form 4: Incyte EVP Steven Stein Reports Acquisition and Disposal of Common Stock

EVP & Chief Medical Officer of Incyte, Steven H. Stein, reports transactions involving Incyte common stock related to performance shares.

Summary

• Steven H. Stein, EVP & Chief Medical Officer of Incyte, filed a Form 4 detailing changes in beneficial ownership of Incyte common stock.
• On April 1, 2025, Stein acquired 37,198 shares of common stock related to performance shares earned upon achieving certain performance criteria.
• These shares will vest on November 30, 2025, contingent upon Stein's continued service with Incyte.
• Also on April 1, 2025, Stein acquired 20,967 shares of common stock related to performance shares earned upon achieving performance criteria.
• These shares will vest on the third anniversary of the July 2, 2022 grant date, subject to continued service.
• The reported transactions leave Stein with a total of 125,132 shares of common stock, including 122,573 unvested shares from previously reported restricted stock units and earned performance shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive. The vesting of performance shares suggests that some performance goals were met, which is mildly positive.

Positives

• The vesting of performance shares indicates that certain performance goals were met, which could be viewed positively.

Risks

• The vesting of the shares is contingent upon the Reporting Person's continued service with the Issuer, so there is a risk of forfeiture if employment terminates before the vesting date.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of performance shares is tied to future service and potentially continued achievement of performance goals.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock. This filing indicates that an executive at Incyte has received shares based on performance, which is a common practice in the biotechnology industry.

Comparison to Industry Standards

• Stock ownership and performance-based compensation are standard practices for executives in publicly traded companies, particularly in the biotechnology sector.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and performance shares as part of their executive compensation packages.
• The specific performance metrics and vesting schedules vary from company to company, but the general principle of aligning executive compensation with company performance is widespread.

Stakeholder Impact

• The vesting of performance shares aligns management's interests with those of shareholders, potentially driving long-term value creation.

Key Dates

Keywords

Form 4, Beneficial Ownership, Incyte, INCY, Steven Stein, Performance Shares, Stock, Vesting